Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)

Arthritis Research

Volumn 3, Issue 3, 2001, Pages 178-182

  Scheja, Agneta ^a   Åkesson, Anita ^a   Geborek, Pierre ^a   Wildt, Marie ^a   Wollheim, Claes B ^b   Wollheim, Frank A ^a   Vischer, Ulrich M ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Systemic sclerosis; Von Willebrand factor; Von Willebrand factor propeptide

Indexed keywords

BIOCHEMICAL MARKER; PEPTIDE DERIVATIVE; PLASMA PROTEIN; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; LUNG DISEASE; PATIENT CODING; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCLERODERMA; SERODIAGNOSIS; SYSTEMIC SCLEROSIS;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROTEIN PRECURSORS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; VON WILLEBRAND FACTOR;

EID: 0035044983     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar295     Document Type: Article

References (32)

1. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon
2. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases
3. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma: Enhanced production and profibrotic action
4. Microalbuminuria and endothelial dysfunction in essential hypertension
5. Features of endothelial dysfunction in early diabetic nephropathy
6. Endothelial dysfunction precedes development of microalbuminuria in IDDM
7. Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death
8. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
9. A sensitive ELISA for von Willebrand factor (vWF:Ag)
10. The effect of ABO blood group on the diagnosis of von Willebrand disease
11. Von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: Improved reliability with parallel determination of the vWf propeptide (vWf:AgII)
12. Alterations of fibronolysis and blood coagulation induced by exercise, and the role of beta-adrenergic-receptor stimulation
13. Exercise induced release of von Willebrand factor: Evidence for hypoxic reperfusion microvascular injury in rheumatoid arthritis
14. Systemic responses in patients with intermittent claudication after treadmill exercise
15. Von Willebrand factor: From cell biology to the clinical management of von Willebrand's disease
16. Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D arginine vasopressin in humans
17. Acute von Willebrand factor secretion from the endothelium in vivo: Assessment through plasma propeptide (vWf:AgII) levels
18. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis
19. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
20. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
21. Computer based quantitative analysis of capillary abnormalities in systemic sclerosis and its relation in plasma concentration of von Willebrand factor
22. Noninvasive estimation of systolic pressure in the right ventricle in patients with tricuspid regurgitation
23. Plasma clearance of a new contrast agent, iohexol: A method for the assessment of glomerular filtration rate
24. Organ manifestations in 100 patients with progressive systemic sclerosis: A comparison between the CREST syndrome and diffuse scleroderma
25. The clinical significance of coagulation abnormalities in systemic sclerosis (scleroderma)
26. Factor VIII complex in progressive systemic sclerosis
27. Raised concentrations of von Willebrand factor antigen in systemic sclerosis
28. Von Willebrand factor, thrombomodulin, tromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis
29. Elevated von Willebrand factor antigen in systemic sclerosis: Relationship to visceral disease
30. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders
31. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis
32. Inverse relation between plasma concentration of von Willebrand factor and CrEDTA clearance in systemic sclerosis